Prometic Therapeutics
Plasma-Derived Therapeutics
Through developing industry-leading affinity technology, Prometic is now using its own affinity technology for the extraction and purification of therapeutics proteins from human plasma.
Through its proprietary Plasma Protein Purification System (PPPS™), Prometic is targeting the extraction of multiple high value proteins from a single plasma sample at unprecedented activity levels. PPPS™ is a sequential, multi-product purification process that employs powerful affinity separation materials to extract and purify commercially important plasma proteins in high yields. Prometic is now operating since late 2013 its own plasma purification facility in Canada where it is recovering therapeutic proteins from plasma for its own clinical trial needs and initial commercial requirements.
Prometic’s strategy is driven through its subsidiaries who work cohesively to pool their skills and develop state-of-the-art processes, equipmentand products. Prometic’s operating subsidiaries work together to deliver these therapeutic products:
- Prometic BioProduction Inc. (PBP), based in Laval, Quebec, Canada
- Prometic BioTherapeutics Inc. (PBT), based in Rockville, MD, USA
- Prometic Bioseparations Ltd. (PBL), based in the United Kingdom (Isle of Man and Cambridge)
Small-Molecule Therapeutics
Prometic’s small-molecule drug discovery is focused on developing orally active drugs that cater for unmet medical applications, such as
- Fibrosis
- Inflammation
- Autoimmune diseases
- Oncology
- Nephropathies
These first-in-class therapeutics typically have efficacy and high safety profiles confirmed in several in vivo experiments, and enjoy strong proprietary positions. Prometic’s Therapeutics is focused on advancing and partnering promising drug candidates following the completion of in vivo proof-of-concept studies, with a number of candidates in the pipeline.
An example of Prometic’s small-molecule drug discovery program is PBI-4050, an orally active lead drug candidate with excellent safety and efficacy profiles confirmed in phase 2 clinical trials in patients suffering from chronic kidney diseases, metabolic syndrome, type 2 diabetes, idiopathic pulmonary fibrosis and alström syndrome . PBI-4050 has a number of ongoing clinical trials targeting rare diseases and unmet medical conditions such as idiopathic pulmonary fibrosis, chronic kidney disease, metabolic syndrome and associated type 2 diabetes. The findings of Prometic’s groundbreaking studies have been presented and published at a number of international conferences.
Prometic’s small molecule Therapeutics operation is spearheaded by its subsidiary centered at PrometicBioSciences Inc., based in Laval, Quebec, Canada. |
